1-ethyl-3-(ethylthio)benzene

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 1-ethyl-3-(ethylthio)benzene
• 英文别名: 3-Ethylphenyl ethyl sulfide；1-ethyl-3-ethylsulfanylbenzene
• 化学式: C₁₀H₁₄S
• mdl: MFCD11617725
• 分子量: 166.287
• InChiKey: BGARPXYTGUAMBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-甲基-3-(甲硫基)苯 以78%的产率得到
  参考文献：
  名称：

  Cabiddu Salvatore, Fattuoni Claudia, Floris Costantino, Melis Stefana, Se+, Tetrahedron, 50 (1994) N 20, S 6037-6048

  摘要：

  DOI：

文献信息

• Metallation reactions. XXI. Metallation of alkyl (alkylthio) benzenes by superbases versus organolithium compounds
  作者：Salvatore Cabiddu、Claudia Fattuoni、Costantino Floris、Stefana Melis、Alessandro Serci

  DOI：10.1016/s0040-4020(01)90456-9

  日期：1994.1

  The metallation regiochemistry of alkyl(alkylthio)benzenes with butyllithium or with the superbasic mixture of butyllithium with potassium tert-butoxide is described. The reaction pattern depends on the substrate and the reagent. Butyllithium monometallates the thiomethylic carbon of methyl (methylthio) benzenes and bimetallates the thiomethylic and the annular carbon ortho to the thioethereal group

  描述了烷基（烷硫基）苯与丁基锂或丁基锂与叔丁醇钾的超碱性混合物的金属化区域化学。反应模式取决于底物和试剂。丁基锂单金属化甲基（甲硫基）苯的硫代甲基碳，而双金属化硫代甲基和与硫醚基团邻位的环状碳。在具有超强碱的情况下，金属化发生在硫代甲基和甲基碳上。与较高同系物的丁基锂的金属化仅将邻位氢取代为硫代烷基，而超碱也将碳原子α攻击为硫代烷基取代基。
• 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS
  申请人：Sugimoto Tomohiro

  公开号：US20110237784A1

  公开（公告）日：2011-09-29

  A novel 10a-azalide compound crosslinked at the 10a- and 12-positions, which is represented by the following formula, and is effective on even Hemophilus influenzae , or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).

  一种新型的10a-azalide化合物，其在10a-和12-位置交联，化学式如下，并且对于Hemophilus influenzae，或者对红霉素产生耐药性的细菌（例如耐药性肺炎球菌和链球菌）具有有效性。
• NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY
  申请人：Almirall, S.A.

  公开号：US20200255478A1

  公开（公告）日：2020-08-13

  The invention relates to peptidic compounds, which peptidic compounds are compounds of formula (I)′, or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer thereof: wherein R 1 ; R 2 ; s; t; u; Aa 78 and G 1 are as defined herein. The peptidic compounds are useful in activating the Nrf2 pathway.
• US8293715B2
  申请人：——

  公开号：US8293715B2

  公开（公告）日：2012-10-23
• [EN] NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY<br/>[FR] NOUVEAUX COMPOSÉS ACTIVANT LA VOIE NRF2
  申请人：ALMIRALL SA

  公开号：WO2019030298A1

  公开（公告）日：2019-02-14

  The invention relates to peptidic compounds, which peptidic compounds are compounds of formula (I)', or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer thereof: (I)', wherein R1; R2; s; t; u; Aa78 and G1 are as defined herein. The peptidic compounds are useful in activating the Nrf2 pathway.